Get 40% Off
🎁 Free Gift Friday: Copy Legendary Investors' Portfolios in One ClickCopy for Free

NVN Liquidation Inc (NOVNQ)

OTC Markets
Currency in USD
Disclaimer
0.01
0.00(0.00%)
Closed

NOVNQ Comments

.... 5.51?
💆🏻‍♂️💆🏻‍♂️💆🏻‍♂️
ha,,,ha....ha.....is 79sen
go to 79$ 🚀🚀🚀🚀
Why?
no.....no.....no.....
This a typical Example of a company Board to choose incompetent CEOs.Great company bad management and leadership.
https://finance.yahoo.com/news/novan-announces-closing-40-million-200100356.html
It seems going down to 3 since the company selling
Hold..Hold Soon 25
Hold..hold…
bulls you have not seen anything yet the stock returned to where it was before the RS the big rise starts on Monday good luck to all
I see most likely back to 1.5 $
plz hel first day
bring them gains to AMC. It's going to be epic
bring them gains to AMC. It's going to be epic
Roth Capital Adjusts Novan PT to $40 From $26,
Will🚀🚀🚀🚀
resistance at 16
it is now starting to grow today
explain more
where do you know from?
it is just a dip
What do you mean?
 i mean it might bounce again
and go higher with each bounce?
The increase is due to the approval of cream to treat infectious skin diseases.very volatile stock.
Its not the approval, its the good results of the cream so far, approval happens after its run through the FDA
Shouldnt have a problem getting to 20+ today!
how? it is going down
what is the reason for increase in this stock?
shoud i buy now?
no to late bro
Good results on the cream
it will go today till 25
Novan end of summer $100
aham... 😏
http://investors.novan.com/news-releases/news-release-details/novan-reports-positive-topline-results-pivotal-phase-3-trial
Novan announces "positive" preclinical results with berdazimer sodium in a SARS-CoV-2 transmission model in golden Syrian hamsters June 10, 2021 08:34 AM ET Briefing.com Related Investments: Novan Inc Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies.Statistically significant, dose-dependent reduction in the amount of virus in the lung with doses as low as 2 mg/mL. Preliminary toxicology and pharmacology study results suggest intranasal administration is well-tolerated and safe.In light of these promising results, the Company is exploring opportunities to develop an anti-viral therapy against COVID-19, the disease caused by the SARS-CoV-2 virus, both internally and potentially through strategic partnerships for this program.
Why they split, may still go down, but two analysts think is is worth over #20 FI you get approval.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.